Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 6 minute read Pharma Industry News Vanda Pharmaceuticals (NASDAQ: VNDA) gains after FDA sets new December 5 date for tradipitant re-review Vanda Pharmaceuticals moves closer to FDA approval for tradipitant in motion sickness while targeting the GLP-1 side effect market. Find out what’s next. byPallavi MadhirajuNovember 28, 2025